Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

FDG-PET/CT as prognostic factor and surveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer

  • Kim, Gi-Won (Department of Radiation Oncology, The Catholic University of Korea School of Medicine) ;
  • Kim, Yeon-Sil (Department of Radiation Oncology, The Catholic University of Korea School of Medicine) ;
  • Han, Eun-Ji (Department of Radiology, The Catholic University of Korea School of Medicine) ;
  • Yoo, Ie-Ryung (Department of Radiology, The Catholic University of Korea School of Medicine) ;
  • Song, Jin-Ho (Department of Radiation Oncology, The Catholic University of Korea School of Medicine) ;
  • Lee, Sang-Nam (Department of Radiation Oncology, The Catholic University of Korea School of Medicine) ;
  • Lee, Jong-Hoon (Department of Radiation Oncology, The Catholic University of Korea School of Medicine) ;
  • Choi, Byung-Oak (Department of Radiation Oncology, The Catholic University of Korea School of Medicine) ;
  • Jang, Hong-Seok (Department of Radiation Oncology, The Catholic University of Korea School of Medicine) ;
  • Yoon, Sei-Chul (Department of Radiation Oncology, The Catholic University of Korea School of Medicine)
  • Received : 2011.08.30
  • Accepted : 2011.10.17
  • Published : 2011.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the prognostic value of metabolic tumor volume (MTV) and maximum standardized uptake value (SUVmax) on initial positron emission tomography-computed tomography (PET-CT) and investigate the clinical value of SUVmax for early detection of locoregional recurrent disease after postoperative radiotherapy in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Materials and Methods: A total of 100 patients with locally advanced HNSCC received primary tumor excision and neck dissection followed by adjuvant radiotherapy with or without chemotherapy. The MTV and SUVmax were measured from primary sites and neck nodes. The prognostic value of MTV and SUVmax were assessed using initial staging PET/CT (study A). Follow-up PET/CT scan available after postoperative concurrent chemoradiotherapy or radiotherapy were evaluated for the SUVmax value and correlated with locoregional recurrence (study B). A receiver operating characteristic (ROC) curve analysis was used to define a threshold value of SUVmax with the highest accuracy for recurrent disease assessment. Results: High MTV (>41 mL) is negative prognostic factor for disease free survival (p = 0.041). Postradiation SUVmax was significantly correlated with locoregional recurrence (hazard ratio, 1.812; 95% confidence interval, 1.361 to 2.413; P < 0.001). A cutoff value of 5.38 from follow-up PET/CT was identified as having maximal accuracy for detecting locoregional recurrence by ROC analysis. Conclusion: MTV at staging work-up was significantly associated with disease free survival. The SUVmax value from follow-up PET/CT showed high diagnostic accuracy for the detection of locoregional recurrence in postoperatively irradiated HNSCC.

Keywords

References

  1. Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 2010;116:4007-13. https://doi.org/10.1002/cncr.25188
  2. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44. https://doi.org/10.1056/NEJMoa032646
  3. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of (18)F-fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002;20:4199-208. https://doi.org/10.1200/JCO.2002.02.590
  4. Ong SC, Schoder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med 2008;49:532-40. https://doi.org/10.2967/jnumed.107.044792
  5. Shintani SA, Foote RL, Lowe VJ, Brown PD, Garces YI, Kasperbauer JL. Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:322-9. https://doi.org/10.1016/j.ijrobp.2007.06.038
  6. Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50:24-9.
  7. Kao J, Vu HL, Genden EM, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer 2009;115:4586-94. https://doi.org/10.1002/cncr.24493
  8. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18:651-8.
  9. Chung MK, Jeong HS, Park SG, et al. Metabolic tumor volume of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 2009;15:5861-8. https://doi.org/10.1158/1078-0432.CCR-08-3290
  10. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;74:1335-41. https://doi.org/10.1016/j.ijrobp.2008.10.060
  11. Liao CT, Chang JT, Wang HM, et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 2009;73:764-71. https://doi.org/10.1016/j.ijrobp.2008.05.004
  12. Koike I, Ohmura M, Hata M, et al. FDG-PET scanning after radiation can predict tumor regrowth three months later. Int J Radiat Oncol Biol Phys 2003;57:1231-8. https://doi.org/10.1016/S0360-3016(03)00757-0
  13. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006;65:1315-22. https://doi.org/10.1016/j.ijrobp.2006.03.015
  14. Yao M, Smith RB, Hoffman HT, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys 2009;74:9-14. https://doi.org/10.1016/j.ijrobp.2008.07.019
  15. Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996;36:999-1004. https://doi.org/10.1016/S0360-3016(96)00430-0
  16. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007;69:328-33. https://doi.org/10.1016/j.ijrobp.2007.04.036
  17. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-18F-fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004;59:1295-300. https://doi.org/10.1016/j.ijrobp.2003.12.039
  18. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997;38:1907-11.
  19. Liao CT, Chang JT, Wang HM, et al. Preoperative 18F-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. Int J Radiat Oncol Biol Phys 2009;74:1054-61. https://doi.org/10.1016/j.ijrobp.2008.09.045
  20. Moeller BJ, Rana V, Cannon BA, et al. Prospective risk-adjusted 18F-Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol 2009;27:2509-15. https://doi.org/10.1200/JCO.2008.19.3300
  21. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. Head Neck 2005;27:175-81. https://doi.org/10.1002/hed.20130
  22. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005;63:991-9. https://doi.org/10.1016/j.ijrobp.2005.03.066

Cited by

  1. Prognostic value of $^{18}F$-fluorodeoxyglucose positron emission tomography, computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with pathologically positive nec vol.30, pp.4, 2012, https://doi.org/10.3857/roj.2012.30.4.173
  2. Early Detection of Recurrent Disease by FDG-PET/CT Leads to Management Changes in Patients With Squamous Cell Cancer of the Head and Neck vol.18, pp.10, 2011, https://doi.org/10.1634/theoncologist.2013-0068
  3. FDG Volumetric Parameters and Survival Outcomes After Definitive Chemoradiotherapy in Patients With Recurrent Head and Neck Squamous Cell Carcinoma vol.203, pp.2, 2011, https://doi.org/10.2214/ajr.13.11654
  4. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-Analysis vol.55, pp.6, 2011, https://doi.org/10.2967/jnumed.113.133801
  5. Tumorvolumenbestimmung : Anforderungen der Strahlentherapie an die moderne radiologische Bildgebung vol.21, pp.5, 2011, https://doi.org/10.1007/s00761-014-2813-0
  6. Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis vol.205, pp.3, 2011, https://doi.org/10.2214/ajr.14.14166
  7. p16 status and interval neck dissection findings after a ‘clinically complete response’ to chemoradiotherapy in oropharyngeal squamous cell carcinoma vol.129, pp.8, 2011, https://doi.org/10.1017/s0022215115001139
  8. Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features vol.207, pp.3, 2016, https://doi.org/10.2214/ajr.15.15730
  9. Predictors of Distant Metastasis after Radical Surgery Followed by Postoperative Radiotherapy with or without Chemotherapy for Oropharyngeal Cancer vol.48, pp.4, 2011, https://doi.org/10.4143/crt.2015.379
  10. Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy vol.38, pp.suppl1, 2011, https://doi.org/10.1002/hed.23988
  11. 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients vol.57, pp.6, 2011, https://doi.org/10.2967/jnumed.115.165480
  12. Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist vol.89, pp.1067, 2011, https://doi.org/10.1259/bjr.20160217
  13. Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study vol.16, pp.None, 2011, https://doi.org/10.1186/s12885-016-2147-y
  14. Clinical impact of PET/CT imaging after adjuvant therapy in patients with oral cavity squamous cell carcinoma vol.44, pp.10, 2011, https://doi.org/10.1007/s00259-017-3713-5
  15. Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer vol.209, pp.2, 2011, https://doi.org/10.2214/ajr.17.18301
  16. Pretreatment metabolic tumor volume as a prognostic factor in HPV‐associated oropharyngeal cancer in the context of AJCC 8th edition staging vol.40, pp.10, 2011, https://doi.org/10.1002/hed.25337
  17. Metabolic tumor volume and conformal radiotherapy based on prognostic PET/CT for treatment of nasopharyngeal carcinoma vol.98, pp.28, 2011, https://doi.org/10.1097/md.0000000000016327
  18. Performance of whole-body 18F-FDG PET/CT as a posttreatment surveillance tool for sinonasal malignancies vol.276, pp.3, 2011, https://doi.org/10.1007/s00405-018-05272-w
  19. Evaluation of the Prognostic Value of FDG PET/CT Parameters for Patients With Surgically Treated Head and Neck Cancer : A Systematic Review vol.146, pp.5, 2011, https://doi.org/10.1001/jamaoto.2020.0014